Stocktoria
SUTRO BIOPHARMA, INC. STRO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-09-27
SUTRO BIOPHARMA, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M |
| R&D expense | $166.4M | $252.0M | $180.4M | $137.2M | $104.4M |
| Operating income | -$158.4M | -$238.5M | -$89.3M | -$128.9M | -$98.5M |
| Income tax | -$93,000 | $2.4M | $18.2M | $2.5M | $0 |
| Net income | -$191.1M | -$227.5M | -$106.8M | -$119.2M | -$105.5M |
| EPS (diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
| Operating cash flow | -$177.2M | -$191.5M | -$111.6M | $3.5M | -$81.7M |
| Cash & equivalents | $58.1M | $190.3M | $69.3M | $47.3M | $30.4M |
| Total assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M |
| Total liabilities | $306.3M | $342.6M | $321.1M | $189.9M | $88.8M |
| Shareholders' equity | -$132.5M | $44.6M | $149.6M | $217.0M | $252.6M |
Source: SEC EDGAR filings · CIK 0001382101 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.